 Immunic, Inc. Nasdaq: IMUX, a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that it will report financial results for the second quarter ended June 30, 2020, and provide a corporate update on Monday, August 3, 2020 before the opening of the U.S. financial markets. 